A subset of mutations could also cooperate with “canonical” mTOR-activating mutations in determining and increasing the final degree of mTORC1 function (e.g. tumor #2 in study by Mohanty et al. with STL11 and TSC1 mutations [24]). The gene discussed is TSC1; the disease is neoplasm.